2015


To access this material please log in or register

Register Authorize
2015/№6

Role of a cardiologist in management of patients receiving antracyclines. Early detection and prevention of antracaycline-induced cardiomyopathy

Ovchinnikov A. G., Vitsenya M. V., Ageev F. T.
Federal State Budgetary Institution, “Russian Cardiology Science and Production Center” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: antracycline-induced cardiomyopathy, doxorubicin, left ventricular ejection fraction, troponin I, total systolic compression of the left ventricle, preventive measures

DOI: 10.18087 / rhfj.2015.6.2159

The antitumor antibiotics, antracyclines, can cause severe LV systolic dysfunction characterized by extremely unfavorable prognosis. The review focuses on mechanisms of antracycline cardiotoxicity and the natural course of antracycline cardiomyopathy. RFs for antracycline cardiomyopathy are presented, among which the total antracycline dose and presence of CVD are the most important ones. The review discusses peculiarities of cardiologic management of patients and specifically stresses detection of the earliest and minor abnormalities of the LV function. Actions aimed at prevention and treatment of antracycline-induced cardiomyopathy are listed.
  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
  2. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, Mertens AC. Late mortality among 5‑year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009 May 10;27 (14):2328–38.
  3. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004 Jun 29;109 (25):3122–31.
  4. Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011 Mar 4;108 (5):619–28.
  5. Mann DL, Felker GM. Heart Failure: A Companion to Braunwald's Heart Disease, 3d ed. – Philadelphia: Elsevier, 2016. – P.689–96.
  6. Ganame J, Claus P, Eyskens B, Uyttebroeck A, Renard M, D’hooge J et al. Acute cardiac functional and morphological changes after Anthracycline infusions in children. Am J Cardiol. 2007 Apr 1;99 (7):974–7.
  7. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun 2;131 (22):1981–8.
  8. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998 Nov;16 (11):3502–8.
  9. Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990 Nov;8 (11):1806–10.
  10. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 Apr 13;342 (15):1077–84.
  11. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006 Nov;5 (6):791–809.
  12. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children's Oncology Group. J Clin Oncol. 2012 May 1;30 (13):1415–21.
  13. van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012 May 1;30 (13):1429–37.
  14. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2‑overexpres­sing breast cancer: NSABP B-31. J Clin Oncol. 2005 Nov 1;23 (31):7811–9.
  15. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010 Oct;7 (10):564–75.
  16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28 (1):1–39.
  17. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009 Feb;22 (2):107–33.
  18. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97 (11):2869–79.
  19. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004 Apr;5 (1):63–9.
  20. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2‑positive breast cancer. N Engl J Med. 2005 Oct 20;353 (16):1673–84.
  21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2‑positive breast cancer. N Engl J Med. 2005 Oct 20;353 (16):1659–72.
  22. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009 Dec 1;27 (34):5685–92.
  23. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002 Mar 1;20 (5):1215–21.
  24. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al. Expert consensus for multimodality imaging evaluation of adult cancer patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 Sep;27 (9):911–39.
  25. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012 Aug 10;30 (23):2876–84.
  26. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-onco­logy and cardio-oncological prevention. J Natl Cancer Inst. 2010 Jan 6;102 (1):14–25.
  27. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013 May;26 (5):493–8.
  28. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014 Jul 1;63 (25 Pt A): 2751–68.
  29. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemothe­rapy. Circulation. 2004 Jun 8;109 (22):2749–54.
  30. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010 Sep 1;28 (25):3910–6.
  31. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011 May 1;107 (9):1375–80.
  32. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014 Sep;89 (9):1287–306.
  33. Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987 Jun;82 (6):1109–18.
  34. Valdivieso M, Burgess MA, Ewer MS, Mackay B, Wallace S, Benjamin RS et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol. 1984 Mar;2 (3):207–14.
  35. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96 (2):133–9.
  36. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014 Sep 2;64 (9):938–45.
  37. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardio­protective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011; (6):CD003917.
  38. Orditura M, Quaglia F, Morgillo F, Martinelli E, Lieto E, De Rosa G et al. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Oncol Rep. 2004 Sep;12 (3):549–56.
  39. O’Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer. 2003 Dec;4 (5):318–28.
  40. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX / Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15 (3):440–9.
  41. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 Dec 5;114 (23):2474–81.
  42. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006 Dec 5;48 (11):2258–62.
  43. Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36‑month follow-up. Am J Hematol. 2010 Nov;85 (11):894–6.
  44. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan 19;55 (3):213–20.
  45. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, ShaikH SL, Mone SM et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002 Dec 1;20 (23):4517–22.
  46. Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S et al. Response of doxorubicin-induced cardiomyo­pathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005 Dec;24 (12):2196–201.
  47. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002 May;13 (5):699–709.
Ovchinnikov A. G., Vitsenya M. V., Ageev F. T. Role of a cardiologist in management of patients receiving antracyclines. Early detection and prevention of antracaycline-induced cardiomyopathy. Russian Heart Failure Journal. 2015;16 (6):396–404

To access this material please log in or register

Register Authorize
Ru En